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Abstract
BACKGROUND: The aim of the study was to analyze the effec-
tiveness of radioactive 131I in hyperthyroid patients with confirmed
lowered iodine uptake as compared to patients with an uptake
of over 30%.
MATERIAL AND METHODS: We retrospectively analyzed
53 consecutive patients aged from 29 to 84 (mean age 60 years)
suffering from hyperthyroidism caused by Graves’ disease or
toxic nodular goitre. The patients were divided into 2 sub-groups:
the 1st with a maximum iodine uptake of 18.7 ± 3.2% (range,
11–23%) — 24 patients; the 2nd with a maximum iodine uptake
of 27.1 ± 2.1% (range, 24–30%) — 29 patients. The control group
consisted of 50 patients treated with 131I with an iodine uptake
of over 30%. Each patient was evaluated before, and 6 months
after, treatment for fT3, fT4 and TSH with ECLIA; TRAb with RIA;
ultrasound with a 7.5 MHz linear probe. The volume of the thy-
roid gland was determined using the Gutekunst method. All
these factors underwent statistical analysis and were considered
along with the results of clinical examinations.
RESULTS: Clinical remission of hyperthyroidism was evident in
79.3% of both sub-groups, in total (83.3% and 75.3%, respec-
tively). TSH was normalized in 62.3% of these patients (54.2%
and 69.0%, respectively). The mean range of TSH levels in-
creased from 0.081mU/ml to 4.0 mU/ml after therapy; that is,
from 0.087 mU/ml to 4.97 mU/ml in the 1st sub-group and from
0.076 mU/ml to 3.3 mU/ml in the 2nd sub-group. The volume of
the thyroid gland was uniformly significantly lower, with a mean
range of 40.5 ml before treatment and 21.7 ml afterwards.
The results seen in both sub-groups were similar; only age and
dose of radioiodine were slightly higher in the 1st, while mean
uptake was higher in the 2nd. By comparison of these results to
those of the control patients, we observed that the values of
TSH, as well as thyroid volume and evidence of clinical remis-
sion, reflected those found in the control group.
The mean dose of 131I was lower in the control group, that is
11.3 m Ci, as compared to the sub-groups as a whole, specifi-
cally, 15.7 mCi. The mean age of patients in the control group
was slightly less than that of the study group (50.8 and 60, res-
pectively).
CONCLUSIONS: 1. The results of the treatment of patients with
a low iodine uptake are similar to the results obtained in the
group of patients with iodine uptake above 30% and therefore
low iodine uptake should not be a contraindication for isotope
I-131 therapy. 2. Additionally, we have demonstrated that a sta-
tistically significant decrease in thyroid volume is observed in
all patients after the iodine isotope treatment which indirectly
proves the effectiveness of the prescribed treatment, and that
low thyroid iodine uptake is more frequently observed in elder-
ly patients and in patients treated with iodine or anti-thyroid
drugs.
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Introduction
The treatment of hyperthyroidism using the I-131 isotope is
a generally accepted and recognised method. However, the me-
thods for establishing treatment doses have been under discussion
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since the early ‘40s, when, for the first time, I-131 was used in
medical treatment. The majority of medical centres use doses
calculated individually for each patient [1, 2]. The method for es-
tablishing the dose is most frequently based on describing an
absorbed dose, taking into consideration the size of the thyroid
gland, the thyroid iodine uptake and the period of effective half-
life of the isotope in the thyroid gland. Some centres use fractio-
nal doses, and the amount depends on the character of the goitre.
According to some authors, low thyroid iodine uptake limits the
possibility of successful treatment, or even makes it impossible.
In their opinion, an absorbed dose, which is too small, does not
give a prognosis for effective treatment [11].
In the Department of Endocrinology, University of Medical
Sciences in Poznań, the treatment of patients with hyperthyroidism
using radioactive iodine has been conducted since 1957. Our ob-
servations have shown that low thyroid iodine uptake is not a con-
traindication for this type of treatment; however, it should be taken
into consideration while establishing the dose of radioiodine.
The aim of this paper was to analyse the 131-I treatment effi-
ciency in patients with hyperthyroidism with proven low thyroid
iodine uptake below 30%, and to compare the results of the treat-
ment obtained in this group to the results in the control group.
Informed consent was given by all treated patients and the study
was approved by the Ethical Committee.
Material and methods
Patients
We retrospectively analysed 53 consecutive patients (44 wom-
en and 9 men) aged from 29 to 84 (mean age 60 ± 13) admitted to
our clinic for 131-I therapy because of hyperthyroidism. All of the
patients came from the same iodine-deficient area. In all patients,
antithyroid drugs had been administered before RAI therapy with a
mean duration of treatment of one year and were withdrawn at least
2 weeks before 131-I therapy. 14 patients were diagnosed with
Graves’ hyperthyroidism on the basis of clinical findings, suppressed
TSH levels, elevated fT4 and fT3 serum concentration and abnor-
mally high elevated serum thyrotropin receptor antibody (TRAb)
levels. 39 patients were diagnosed with toxic nodular goitre on the
basis of clinical and biochemical findings of hyperthyroidism in the
presence of a nodular goitre. The patients were divided into two
groups. The first group included 24 individuals with maximum io-
dine uptake of 18.7 ± 3.25% (range, 11–23%); the second group
included 29 individuals with iodine uptake of 27.1 ± 2.1% (range,
24–30%). The control group consisted of 50 consecutive patients
treated with I-131,with iodine uptake of more than 30%. Within the
control group, 11 patients were diagnosed with toxic nodular goitre
and 39 patients with Graves’ hyperthyroidism.
Methods
Radioiodine uptake — was measured by a previously cali-
brated scintillation counter (Polon, Warsaw, Poland) 24 h after ad-
ministering a tracer dose of iodine-131 (10 mCi). Measurement
was performed for 2 minutes with the patient positioned upright
and the anterior surface of the neck 20 cm from the detector.
Scintigraphy — was performed using a g-camera (Nucline TH/33,
Hungary). The images were interpreted using both computer screen
(256 grey scale) and film by an experienced nuclear medicine physician.
Thyroid ultrasonography — using Aloka SSD 1100 with a linear
probe of 7.5 MHz (Tokyo, Japan) was performed in every patient for
exact determination of thyroid volume with the ellipsoid formula: width
[cm] × length [cm] × thickness [cm] × p/6 for each lobe.
Biochemical and immunological investigation — each pa-
tient underwent the following examinations: registration of serum
fT3, fT4 and TSH concentrations with the ECLIA method and se-
rum TSH receptor antibodies (TRAb) levels measurement with RIA
method.
Dose calculation — the individual delivered dose (D) for 131-I
therapy was calculated by the following formula: D (mCi) = con-
stant × target dose (Gy) × thyroid volume (ml)/iodine uptake at
24 h (%) × effective half-life of 131-I (days). The target dose was
50 Gy.
Outcome assessment — all patients were followed up by
clinical assessment and were checked by ultrasonography as well
as for fT3, fT4, TSH, and TRAb levels 6 months after radioiodine
therapy. They were classified into three groups according to their
thyroid function as hypothyroid (elevated serum TSH concentra-
tion and low serum fT3 and fT4 concentration), euthyroid (normal
serum fT3, fT4 and TSH concentration) or hyperthyroid (su-
ppressed TSH levels and raised serum fT3 and fT4 concentration).
No side-effects of radioiodine were noted at follow-up examination.
Statistical analysis of the obtained results was conducted
using the non-parametric Mann-Whitney test for the unpaired val-
ues, and the Spearman test for the paired values.
Results
In 79.3% of examined patients (83.3% and 75.9% in both sub-
groups respectively) the absence of clinical features of hyperthy-
roidism (responders to RAI therapy) was observed 6 months after
treatment. Similar results were obtained in the control group
(p > 0.05) (Table 1).
In the group of patients with low iodine uptake, continuing low
TSH values (persistent hyperthyroidism) were observed in 20.7%
(11) of cases, whereas in the control group, in 24% (12) of pa-
tients. Incorrect high TSH values occurred in 17% (9) of examined
patients, and in the control group in 16% (8) of patients. Norma-
lized TSH values were observed in 62.3% (33) of the examined
patients (54.2% and 69% in both subgroups respectively), and in
60% (30) of patients from the control group. Average TSH values
in both tested groups increased from 0.081 mU/ml before treat-
ment, to 4.0 mU/ml after treatment (p < 0.0001). In respective sub-
groups: group I — from 0.087 mU/ml to 4.97 mU/ml, and group II
— from 0.076 mU/ml to 3.3 mU/ml (Figure 1).
Thyroid volume in the examined group decreased in a statisti-
cally significant way in all patients, from an average 40.5 ml before
treatment, to 21.7 ml after treatment (p < 0.0001). Analysing the
patients depending on diagnosis, a statistically significant differ-
ence in the change of thyroid volume was observed (D). In the pa-
tients with Graves’ disease, thyroid volume after treatment with ra-
dioiodine amounted to 33.4% of the initial value (from 29.42 ml to
10.0 ml), whereas in the patients with toxic nodular goitre, it amount-
ed to 60.7% of the initial value (from 42.5 ml to 25.83 ml) (Figure 2).
In the control group, the average volume before treatment
amounted to 43.4 ml and decreased in a statistically significant
way to 17.4 ml (p < 0.0001). At the same time, the degree of the
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change in thyroid volume obtained after treatment in the tested
group did not differ in a statistically significant way in comparison
to the control group. (Figure 3).
The average thyroid iodine uptake in the tested group (23.3%)
was smaller in a statistically significant way in comparison to the
control group (63.3%) (p < 0.0001). The average age of the pa-
tients from the control group was 50.8 and was lower in a statisti-
cally significant way than in the tested group 60.0 (p = 0.0037)
(Table 2).
The average 131-I dose was smaller in the control group and
amounted to 11.3 mCi, in comparison to the tested group — 15.7
mCi (Group I — 16.5 mCi, Group II — 15.0 mCi, respectively),
which constitutes a statistically significant difference (p = 0.0059).
(Figure 4).
The results obtained in the particular subgroups were similar,
however; only age and dose were slightly higher in the first sub-
group, with the average iodine uptake slightly larger in the second
subgroup.
Discussion
In 1941, the I-131 isotope was used for the first time in medi-
cal treatment. Since then, this type of therapy has been widely
used in the treatment of hyperthyroidism [1, 2]. 131-I therapy is
a safe and effective method, and with the exception of hypothy-
roidism no other serious side effects were observed. There is no
evidence of increased risk of thyroid gland cancer caused by the
radioiodine treatment. The frequency of leukaemia and other pro-
liferative diseases is similar to those in the general population [3].
Although radioiodine therapy may sometimes cause slight post
radiation thyroiditis, temporary exacerbation of thyreotoxicosis
symptoms, vomiting and lack of appetite or in the case of Graves’
disease and in smokers [4], ocular symptoms aggravation, all the
Figure 1. Change in TSH value after I-131 treatment (U/ml).
Table 1. Clinical status before and after treatment
Clinical condition Clinical condition 6 months
before treatment  after treatment
Thyreotoxicosis Hypothyroidism Euthyroidism Thyreotoxicosis
n % n % n % n %
Group I 24 100 7 29.1 13 54.2 4 16.7
Group II 29 100 2 6.9 20 69.0 7 24.1
Total 53 100 9 17.0 33 62.3 11 20.7
Control 50 100 8 16.0 30 60.0 12 24.0
Figure 2. Change in thyroid volume depending on diagnosis.
Figure 3. Change in thyroid volume after treatment (ml).
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registered side effects are incomparable to the effects of thyreoto-
xicosis which may lead to the death of the patient. They are also
incomparable to the unpredictable allergic reactions to thyreo-
statics, anaesthetics and surgical complications.
Despite such a long period of using this method, the optimal
method for calculation of the dose is still a matter of debate. It is
questionable whether the adjusted dose has any benefit over the
fixed dose, and which factors should be incorporated into the
dosimetric formula.
Some authors claim that patients with thyreotoxicosis should
be treated with ablative fixed-doses that completely eliminate hy-
perthyroidism, leading to the permanent hypofunction of the or-
gan within 1 year [5–9]. They emphasize that this is proof of the
cure of thyreotoxicosis, and in a period of TSH determination
using hypersensitive methods as well as widely available L-thyroxin
preparations, a substitute therapy may be quickly and effectively
applied without endangering patients to the unbeneficial results
of hypothyreosis. Treatment using thyroxin is one of the safest
and most effective methods of controlling thyroid gland function.
Other authors consider the occurrence of hypothyroidism af-
ter radioiodine treatment as a significant side effect and propose
a more conservative approach where the aim is to achieve a dura-
ble euthyroid state and to avoid hypothyroidism [10]. In various
publications, the percentage of patients with hypothyreosis ranges
from 20% to 50%, depending on the method of dose calculation.
In our study, we calculated an individual dose for each patient
and the frequency of hypothyroidism amounted to 17%, which
was similar to the control group. Therefore, we postulated that
adjusted-dose regimens reduce the likelihood, or at least delay
the onset, of permanent hypothyroidism.
 The purpose of radioiodine treatment in patients with low io-
dine uptake remains questionable [11]. Some studies report that
the therapeutic effect in patients with low iodine uptake is much
lower than in patients with iodine uptake above 30% [12] or even
that low thyroidal 131-I uptake makes radioiodine therapy unfea-
sible [13]. Unfortunately, iodine supplementation of dietary salt
and the common use of preparations of vitamins containing io-
dine cause low iodine uptake in many patients with thyreotoxico-
sis. Assuming that the limit of iodine uptake, from which radioiod-
ine therapy may be applied, is 30%, or as some authors claim
40%, a large group of patients should be disqualified from this
type of treatment [11]. However, other authors have demonstra-
ted that individuals with higher 24-h uptake value are more likely to
fail to respond to radioiodine treatment and to persist in a hyper-
thyroid state [14]. Moreover, according to the results of a recent
study [15], patients with the lowest pretherapeutic RAI uptakes
show the highest success rates after RAI treatment. Our study
supports these findings. The treatment effectiveness in patients
with a low thyroid iodine uptake amounted to 79.2%, and was
similar to the control group. Although the average therapeutic dose
in the tested group amounted to 15.7 mCi and was larger than the
dose administered to the control group (11.3 mCi), no higher inci-
dence of hypothyroidism was observed. This proves that a higher
dose of 131-I is warranted in patients with low iodine uptake and
guarantees a success rate similar to those in patients with iodine
uptake above 30%.
 Reduction in thyroid size [16] is indirect proof of the benefi-
cial effects of radioiodine on the thyroid gland. In our study,
a statistically significant decrease in the organ volume was
assessed 3 months after the therapy. The results were similar to
those obtained previously in this clinic [17].
Pedersen and Kirkegaard proved that treatment effective-
ness depends on the initial concentration of TSH [18]. The higher
the TSH concentration before treatment, the higher the effective-
ness of iodine therapy. Our tests, although carried out on a small-
er number of patients, confirm those observations. In the first test-
ed subgroup, the TSH concentration amounted to 0.087 mU/ml,
and the disease remission occurred in 83.3% of patients. In the
second subgroup, the TSH concentration amounted to 0.076 mU/ml
and remission was observed in a smaller number of patients — 75.8%.
Sowiński [19] proved the relationship between the initial re-
sults of T3, T4 and rT3, and the effectiveness of treatment with
131-Iodine isotope. The higher the initial values of T3 and T4, the
worse the therapeutic effect. An inverse dependence was observed
Table 2. Results of treatment
TSH Thyroid volume Age Uptake Dose Responders
[mU/ml] [ml] (years) I (%) [mCi] to RAI therapy
Before After Before After
Group I 0.087 ± 0.039 4.97 ± 8.929 34.4 ± 20.84 20.1 ± 16.89 62.9 ± 11.4 18.8 ± 3.2 16.5 ± 9.13 83.3
Group II 0.076 ± 0.054 3.3 ± 8.163 42.8 ± 29.02 22.9 ± 17.03 57.5 ± 14.3 27.1 ± 2.1 15.0 ± 9.43 75.9
Average 0.081 ± 0.047 4.0 ± 8.474 40.5 ± 25.76 21.7 ± 16.86 60.0 ± 13.2 23.3 ± 4.9 15.7 ± 9.24 79.3
Control 0.09 ± 0.049 3.65 ± 9.021 43.4 ± 28.84 17.4 ± 15.3 50.8 ± 15.1 63.3 ± 15.7 11.3 ± 7.46 76.0
Figure 4. Average I-131 dose (mCi).
(%)
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in rT3. It seems that for larger TSH values and lower values of T3
and T4, the clinical symptoms of thyreotoxicosis are less intensi-
fied and therefore the percentage of successful treatment in those
patients is higher.
It has been shown in this research that the mean age of the
patients with low thyroid iodine uptake is higher in comparison to
the control group. Additionally, in some patients from this group,
clinical symptoms of circulatory insufficiency and cerebral arterio-
sclerosis were observed, which disqualified the majority from sur-
gical procedure. The ineffective treatment with anti-thyroid drugs,
existing contraindications and the patients’ fear of surgical treat-
ment implies that many patients suffering from thyreotoxicosis are
recommended for radioiodine treatment.
Summing up, therapy of hyperthyroidism in patients with
a low thyroid iodine uptake is as effective as in other patients.
Iodine uptake below 30% does not restrict the use of iodine the-
rapy and, excluding the health benefits, may lower the cost of
treatment in patients with thyreotoxicosis.
Conclusions
On the basis of the obtained results, the following conclusions
were drawn:
1. The results of the treatment of patients with a low iodine up-
take are similar to the results obtained in the group of patients
with iodine uptake above 30%, and therefore low iodine uptake
should not be a contraindication for isotope I-131 therapy.
2. Additionally, we have demonstrated that a statistically signifi-
cant decrease in thyroid volume is observed in all patients
after the iodine isotope treatment, which indirectly proves the
effectiveness of the prescribed treatment, and that low thy-
roid iodine uptake is more frequently observed in elderly pa-
tients and in patients treated with iodine or anti-thyroid drugs.
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